Literature DB >> 24927614

Adult human liver contains intermediate-type proteasomes with different enzymatic properties.

Sabrina Gohlke1, Alexander Kloss1, Michael Tsokos2, Kathrin Textoris-Taube1, Christin Keller1, Peter-Michael Kloetzel1, Burkhardt Dahlmann1.   

Abstract

BACKGROUND: The 20S proteasome is the proteolytic core of the major intracellular protein degradative system, the ubiquitin-proteasome system. Since little is known about proteasomes of human liver, we have investigated the proteasome spectrum in adult human liver.
MATERIAL AND METHODS: 20S proteasomes were chromatographically purified from adult human liver and from HuH7 cells. They were divided into subpopulations and subtypes and characterized with regard to their proteolytic activities using short fluorogenic oligo- and long poly-peptide substrates. Their subunit composition was studied by immunoblotting.
RESULTS: Proteasomes from adult human liver tissue can be separated into three subpopulations (I, II, III), each of which is composed of several subtypes, which total to a spectrum of 14 different subtypes. Two minor subtypes contain only the immuno-subunits β1i and β5i but not their standard counterparts; all others are intermediate subtypes containing β1 and β5 standard- and β1i and β5i immuno-subunits in various compositions. With regard to the proteolytic activities we observed that a decreasing content of subunit β1i in the subtypes goes along with a decreasing ratio of chymotrypsin-like/caspase-like activity, whereas the degradation rate of a 30 mer polypeptide substrate increased with decreasing β1i content. By comparison, 20S proteasomes from HuH7 cells do not contain immuno-subunits but are pure standard proteasomes, which can be separated into three subtypes.
CONCLUSION: These findings suggest that adult human liver contains a spectrum of 14 different 20S proteasome subtypes with different enzymatic properties reflecting most probably an adaptive response of liver cell functions to challenging factors during lifetime.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24927614

Source DB:  PubMed          Journal:  Ann Hepatol        ISSN: 1665-2681            Impact factor:   2.400


  9 in total

1.  Elucidating the catalytic subunit composition of distinct proteasome subtypes: a crosslinking approach employing bifunctional activity-based probes.

Authors:  Kimberly Cornish Carmony; Lalit Kumar Sharma; Do-Min Lee; Ji Eun Park; Wooin Lee; Kyung-Bo Kim
Journal:  Chembiochem       Date:  2014-12-04       Impact factor: 3.164

2.  Regulation of immunoproteasome function in the lung.

Authors:  Ilona E Keller; Oliver Vosyka; Shinji Takenaka; Alexander Kloß; Burkhardt Dahlmann; Lianne I Willems; Martijn Verdoes; Hermen S Overkleeft; Elisabeth Marcos; Serge Adnot; Stefanie M Hauck; Clemens Ruppert; Andreas Günther; Susanne Herold; Shinji Ohno; Heiko Adler; Oliver Eickelberg; Silke Meiners
Journal:  Sci Rep       Date:  2015-05-19       Impact factor: 4.379

3.  Inhibition of immunoproteasome reduces infarction volume and attenuates inflammatory reaction in a rat model of ischemic stroke.

Authors:  X Chen; X Zhang; Y Wang; H Lei; H Su; J Zeng; Z Pei; R Huang
Journal:  Cell Death Dis       Date:  2015-01-29       Impact factor: 8.469

4.  Proteasome β5i Subunit Deficiency Affects Opsonin Synthesis and Aggravates Pneumococcal Pneumonia.

Authors:  Felicia Kirschner; Katrin Reppe; Nadine Andresen; Martin Witzenrath; Frédéric Ebstein; Peter-Michael Kloetzel
Journal:  PLoS One       Date:  2016-04-21       Impact factor: 3.240

Review 5.  Biological consequences of structural and functional proteasome diversity.

Authors:  Alexey V Morozov; Vadim L Karpov
Journal:  Heliyon       Date:  2018-11-02

Review 6.  The Ubiquitin-Proteasome System in Immune Cells.

Authors:  Gonca Çetin; Sandro Klafack; Maja Studencka-Turski; Elke Krüger; Frédéric Ebstein
Journal:  Biomolecules       Date:  2021-01-05

7.  Proteasomal adaptations to FDA-approved proteasome inhibitors: a potential mechanism for drug resistance?

Authors:  Kyung Bo Kim
Journal:  Cancer Drug Resist       Date:  2021-05-30

8.  Blood Immunoproteasome Activity Is Regulated by Sex, Age and in Chronic Inflammatory Diseases: A First Population-Based Study.

Authors:  Ilona Elisabeth Kammerl; Claudia Flexeder; Stefan Karrasch; Barbara Thorand; Margit Heier; Annette Peters; Holger Schulz; Silke Meiners
Journal:  Cells       Date:  2021-11-28       Impact factor: 6.600

Review 9.  Out of Control: The Role of the Ubiquitin Proteasome System in Skeletal Muscle during Inflammation.

Authors:  Stefanie Haberecht-Müller; Elke Krüger; Jens Fielitz
Journal:  Biomolecules       Date:  2021-09-08
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.